• Hualan Bio Eng reported a net income of 261.8 million yuan in the 1st quarter.
• The company achieved a revenue of 787.3 million yuan in the same period.
• Investment sentiment for the company is high, with 21 recommendations to buy, 0 to hold, and only 1 sell call.
A look at Hualan Biological Engineering Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysing the Smartkarma Smart Scores for Hualan Biological Engineering reveals a promising long-term outlook. With strong ratings in Dividend, Resilience, and Momentum, the company demonstrates solid fundamentals. Hualan Biological Engineering‘s focus on producing and marketing key biological products indicates stability and growth potential in the market.
The Value, Growth, and Resilience scores reflect a company that is positioned to weather market fluctuations and deliver consistent returns to investors. With a noteworthy emphasis on dividends and a robust momentum score, Hualan Biological Engineering appears well-equipped to navigate challenges and seize opportunities for sustained success in the foreseeable future.
Summary: Hualan Biological Engineering Inc. specializes in producing and marketing human serum albumin (HSA), gamma globulin, frozen prothrombin (PCC), and related biological products, with a solid foundation and growth potential indicated by its Smart Scores in Dividend, Resilience, and Momentum.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
